Brought to you by 
Shire gets ex-US rights to three Amicus compounds; terminated
03 Dec 2015
Executive Summary
Amicus Therapeutics (developing oral drugs to treat various genetic diseases) licensed Shire PLC's Shire Human Genetic Therapies worldwide rights outside the US to its Phase II Amigal (migalastat) for Fabry disease, Phase II Plicera (isofagomine tartrate) for Gaucher disease, and Phase I AT2220 (deoxynojirimycin) for Pompe disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets ex-US rights to three Amicus compounds; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice